Given the importance of TLR7 signaling in activating autoreactive B cells in SLE, we investigated whether CD22 crosslinking by Emab might affect B-cell activation in response to BCR and/or TLR7 stimulation. This evidence concerns the gene CD22 and systemic lupus erythematosus.